Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health concern. Despite advancements in diagnostic tools and therapeutic strategies, the disease's management continues to pose challenges due to the emerging antibiotic resistance. This article outlines the updated approach to diagnosing and treating enteric fever.
Timely and accurate diagnosis of enteric fever is critical. Traditional culture methods, though considered the gold standard, are time-consuming and have low sensitivity. Therefore, serological tests like Widal and Typhidot have been widely used. However, their specificity and sensitivity have been questioned. Recent advancements include molecular techniques like PCR and next-generation sequencing, offering high sensitivity and specificity, though their application is limited in resource-poor settings.
Antibiotic therapy remains the mainstay of enteric fever treatment. However, the increasing prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains necessitates a change in the treatment approach. Fluoroquinolones, once considered first-line therapy, are now recommended as second-line due to resistance. Current guidelines suggest using azithromycin or ceftriaxone as first-line therapy for uncomplicated cases, while resistant cases may require newer agents like carbapenems.
Prevention strategies include improving sanitation, safe water supply, and vaccination. Ty21a and Vi polysaccharide vaccines have shown efficacy, though their protection is short-lived. The newly introduced conjugate vaccine (Typbar-TCV) offers longer protection and is recommended for endemic regions.
Enteric fever management requires an updated approach considering the changing epidemiological trends and emerging resistance. While newer diagnostic and therapeutic strategies offer hope, their application needs to be tailored to the local epidemiological and resource context. Furthermore, prevention through improved sanitation, safe water, and vaccination remains crucial in controlling the disease.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation